



Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills
Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507

Tel: + 91 40 4900 2900
Fax: + 91 40 4900 2999
Email: mail@drreddys.com
Web: www.drreddys.com

January 21, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited. (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Q3 FY26 Unaudited Financial Results Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation on the Unaudited Financial Results of the Company for the quarter ended December 31, 2025.

This is for your information and records.

Thanking you.

Yours faithfully,
For Dr. Reddy's Laboratories Limited

K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR

Encl: as above



Dr. Reddy's Q3FY26 RESULTS UPDATE

21 JANUARY 2026

Safe Harbor Statement



This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as "anticipates", "believes", "estimates", "expects", "intends", "plans", "predicts", "projects" and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements.

For more detailed information on the risks and uncertainties associated with the Company's business activities, please see the company's annual report filed in Form 20-F with the US SEC for the fiscal year ended March 31, 2025, quarter ended June 30, 2025, September 30, 2025, and our other filings with US SEC. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events.

Q3FY26 Financial Highlights



Double-digit growth in base business[^]; overall steady profitability, despite product specific headwinds

Revenues

₹ 8,727 Cr

↑ 4.4%YoY ↓ 0.9%QoQ

EBITDA | EBITDA %

₹ 2,049 Cr | 23.5%

↓ 11%YoY ↓ 13%QoQ

PBT | PBT %

₹ 1,543 Cr | 17.7%

↓ 18%YoY ↓ 16%QoQ

*PAT | PAT %

₹ 1,210 Cr | 13.9%

↓ 14%YoY ↓ 16%QoQ

*Attributable to Equity shareholders

- Revenue growth @4.4%
- Reported EBITDA Margin @23.5%
- Annualised RoCE at 20.4%
- Net Cash surplus at ₹3,069 Cr


One-time provision

Impact of new Labour Codes in India

UNDERLYING FINANCIALS (Adjusted for One-off)

Underlying %

54.1% 24.8% 19.0%



One-time provision related to new Labour Codes in India

As Reported

[^]Excluding Lenalidomide

Q3FY26 Business Highlights

Continued progress on strategic priorities

- Strategic collaboration with **Immutep** for commercialisation of a novel, immunotherapy oncology drug, **Eftilagimod Alfa**, in key Emerging Markets.
- Launched **Hevaxin®**, a novel, recombinant vaccine for prevention of Hepatitis-E virus infection in India.
- Completed **integration** of 85% of acquired **NRT** business by value.
- Received **Marketing Authorisation** for **Semaglutide** injection in **India** from DCGI.
- **Filed BLA** for **abatacept** biosimilar (IV) for US in Dec'25.
- Received **EC for Europe** and **MHRA, UK** approval for **denosumab** biosimilar. Launched in **Germany** in Dec'25.



ESG

- Announced **Science-Based Net Zero Climate Targets** - only Indian Pharma co to commit to such a target by FY2045.
- Leadership position in **2025 CDP Water Security & Climate Change**.
- CII Award** of Merit for Excellence in 4R category, amongst top 25 in India.
- TÜV SÜD** South Asia certification for **Net Positive Water Impact**.
- India's Top 100 Great Places to Work®**, 2nd year in a row.
- Industrial Green Chemistry World** Award 2025.
- 7 Eminence Awards** at Pharmaceutical Manufacturing & Automation Conclave.

OTHER UPDATES


- USFDA conducted **GMP** inspection at **CTO-SEZ** API facility (Srikakulam), issued Form 483 with zero observations.
- USFDA conducted **GMP & PAI** inspection at **FTO-SEZ PU-01** formulations facility (Srikakulam), issued Form 483 with five observations. Response submitted within timelines.
- USFDA issued a **PAAL** as part of ongoing review of responses submitted to observations at Bachupally biologics facility for **Rituximab** biosimilar.
- Received **NON** from **Health Canada** for **Semaglutide** Injection. Response submitted within timelines.
- Received **CRL** from USFDA for **denosumab** biosimilar BLA, related to observations at Alvotech's facility.

Q3FY26 Revenue Split

Dr.Reddy's 

Broad-based growth, aided by forex; moderated by product-specific headwinds in the US

REVENUE BY SEGMENT



Global Generics

₹ 7,911 Cr

↑ 7%YoY ↑ 1%QoQ

PSAI

₹ 802 Cr

↓ 2%YoY ↓ 15%QoQ

GLOBAL GENERICS SPLIT

North America

₹ 2,964 Cr


↓ 12%YoY ↓ 9%QoQ



Europe

₹ 1,448 Cr

↑ 20%YoY ↑ 5%QoQ



India

₹ 1,603 Cr

↑ 19%YoY ↑ 2%QoQ


Emerging Markets

₹ 1,896 Cr


↑ 32%YoY ↑ 15%QoQ

Key Financial Metrics

Sustaining growth & profitability, while investing for the future



*24.8%, excl. one-time provision related to new Labour Codes in India




*Before acquisition related payouts

^Net Surplus (Adjusted for non-current cash & borrowings) stood at ₹.3069 Cr as on 31 Dec '25

Q3FY26 North America Performance

Dr.Reddy's 

Moderated due to lower Lenalidomide sales and continued pricing pressure



Revenues
₹ 2,964 Cr

↓ 12%YoY ↓ 9%QoQ

Declined due to lower Lenalidomide sales
and product specific price erosion

Historical Revenues (₹ Cr)

Q3FY26	2,964
Q2FY26	3,241
Q1FY26	3,412
Q4FY25	3,559
Q3FY25	3,383

MARKET PERFORMANCE

2.6% vs -0.3%

DRL Growth vs US Generics Market

(Excl. Lenalidomide)

*As per IQVIA MQT Nov' 25

NEW LAUNCHES

6 **18**
Q3FY26 9MFY26

NEW ANDA FILINGS

4 **10**
Q3FY26 9MFY26

PRICE EROSION

MODERATE

PENDING APPROVAL

71 **2**
ANDAs NDAs

Includes 44 Para IVs & 21 FTFs

As of Dec'25

KEY UPDATES

- First-to-market launch of **Olopatadine Hydrochloride Ophthalmic Solution, USP** in the US
- Filed Biologics Licence Application (BLA) for **abatacept biosimilar** for the Intravenous (IV) presentation for the US market in Dec '25.



Q3FY26 India Performance

Robust double-digit growth, continued outperformance of IPM



KEY UPDATES




- Launched **Hevaxin®**, a novel, recombinant vaccine for prevention of Hepatitis-E virus infection.
- Received **Marketing Authorisation** from Drug Controller General of India (DCGI) and secured **local manufacturing licenses** for **Semaglutide** injection.



Q3FY26 Emerging Markets Performance



New product launches & favourable forex driving growth



Q3FY26 Europe Performance

Dr.Reddy's 

Momentum in NRT business, new launches, aided by forex tailwinds



Revenues

₹ 1,448 Cr

↑ 20%YoY ↑ 5%QoQ

Growth Drivers : Acquired NRT business (now in base), new product launches, favourable forex, offset by price erosion

Historical Revenues (₹ Cr)

Q3FY26	1,448
Q2FY26	1,376
Q1FY26	1,274
Q4FY25	1,275
Q3FY25	1,210

COUNTRIES
PRESENT IN
20

NEW GX PRODUCT LAUNCHES

10 **31**

Q3FY26 9MFY26

NEW FILINGS


3 **11**

Q3FY26 9MFY26

KEY UPDATES



- NRT integration** progressing well; 85% business value integrated.
- Received **European Commission** and **MHRA, UK** approval for **denosumab biosimilar**. Launched in **Germany** in Dec'25.

REVENUE SPLIT



Q3FY26 PSAI Performance

Adverse Product mix impacting gross margins



KEY UPDATES

- Non-binding strategic cooperation term sheet signed with **Hybio Pharmaceutical** on Peptide APIs.
- Aurigene Pharmaceutical Services Limited (APSL)**, our CDMO business, served as exclusive API manufacturer for two of 46 Novel Drugs approved by USFDA in 2025.
- APSL delivered three discovery programs through its in-house, AI assisted drug discovery platform, **Aurigene.AI**.



In Summary

A diversified business model with broad based levers



STRENGTHEN CORE BUSINESSES ACROSS MARKETS

ADVANCE KEY PIPELINE PRODUCTS (SEMAGLUTIDE, ABATACEPT)

DRIVE EFFICIENCIES THROUGH BETTER OPERATIONAL LEVERAGE

AUGMENT ORGANIC GROWTH WITH M&A AND IN-LICENSING

STRENGTHEN CAPABILITIES – PEOPLE, DIGITAL, PROCESSES

FOCUS ON QUALITY, COMPLIANCE, SUSTAINABILITY



We accelerate access to affordable and innovative medicines because

Good Health Can't Wait.

~756mn patients reached globally

\$3.8bn Revenue

17% Revenue Growth

28% EBITDA Margin

~28% RoCE

26,000+ Employees globally

57 Nationalities (Employees)

83 Markets served

32 Plants (Manufacturing & R&D)

At a glance



● Sales and Other Offices

● Research and Development Centres

● Manufacturing Facilities

● Headquarters

All information as of FY25

Consolidated Income Statement



Particulars (₹ Cr)	Q3FY26	Q3FY25	YoY Gr %	Q2FY26	QoQ Gr%	9MFY26	9MFY25	YoY Gr %
Revenues	8,727	8,359	4.4	8,805	(0.9)	26,077	24,048	8.4
Cost of Revenues	4,046	3,453	17	3,991	1	11,720	9,731	20
Gross Profit	4,681	4,905	(5)	4,814	(3)	14,357	14,317	0
% of Revenues	53.6%	58.7%		54.7%		55.1%	59.5%	
Selling, General & Administrative Expenses	2,692	2,412	12	2,644	2	7,900	6,982	13
% of Revenues	30.8%	28.9%		30.0%		30.3%	29.0%	
Research & Development Expenses	615	666	(8)	620	(1)	1,860	2,012	(8)
% of Revenues	7.0%	8.0%		7.0%		7.1%	8.4%	
Impairment of Non-Current Assets, net	27	0	(6,875)	66	(59)	93	93	1
Other (Income)/Expense, net	(77)	(44)	75	(267)	(71)	(418)	(189)	121
Results from Operating Activities	1,424	1,872	(24)	1,751	(19)	4,923	5,420	(9)
Finance (Income)/Expense, net	(117)	2	(5,940)	(77)	51	(351)	(237)	48
Share of Profit of Equity Accounted Investees, net of tax	(2)	(4)	(45)	(6)	(63)	(9)	(16)	(46)
Profit before Income Tax	1,543	1,874	(18)	1,835	(16)	5,283	5,673	(7)
% of Revenues	17.7%	22.4%		20.8%		20.3%	23.6%	
Income Tax Expense	353	470	(25)	408	(13)	1,257	1,536	(18)
Profit for the Period	1,190	1,404	(15)	1,427	(17)	4,026	4,137	(3)
Attributable to Equity holders of the parent company	1,210	1,413	(14)	1,437	(16)	4,065	4,061	0
% of Revenues	13.9%	16.9%		16.3%		15.6%	16.9%	
Attributable to Non-controlling interests	(20)	(10)	113	(10)	95	(39)	77	(2)
Diluted Earnings per Share (EPS) in ₹	14.52	16.94	(14)	17.25	(16)	48.78	48.68	0
EBITDA	2,049	2,298	(11)	2,351	(13)	6,679	6,738	(3)
% of Revenues	23.5%	27.5%		26.7%		25.6%	28.0%	

About Key Metrics and Non-GAAP Financial Measures

This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are adjusted to exclude or include amounts, as the case may be, from the most directly comparable financial measure calculated and presented in accordance with IFRS.

The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS. Our non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. These measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.

We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.

For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please refer to "Reconciliation of GAAP to Non-GAAP Results" table in the press release.



Good Health Can't Wait.